Leadership & Board - Aziyo

Leading Us Forward.

Decades of diverse experience & insight.

Aziyo’s executives bring decades of experience in regenerative medicine, biomedical engineering and biologics processing. With their diverse experiences, they provide insight and guidance that equips us to continually innovate our products to best serve patients and their families.

The Leadership Team.

Ronald Lloyd

President & CEO

Ron Lloyd has served as our President and Chief Executive Officer and as a member of our board of directors since June 2018. Prior to joining Aziyo, Mr. Lloyd served as Executive Vice President and President of Hospital Therapies of Mallinckrodt Pharmaceuticals, a publicly traded global pharmaceuticals company, from January 2016 to May 2018, where Mr. Lloyd reorganized the hospital business structure and completed four business development transactions. Mr. Lloyd also served as President of Immunology at Baxter, a publicly traded healthcare company, from April 2003 to December 2015, where Mr. Lloyd developed and implemented strategies to build the plasma business, the U.S. bioscience business and the regenerative medicine business. Mr. Lloyd holds a Master of Science in Industrial Administration from Carnegie Mellon University and a B.A. in Management Science from Westminster College.

Read More…

His tenure at Baxter included a leadership role in developing and implementing strategies to build a regenerative medicine business. Before joining Baxter, Ron served in a number of capacities at Abbott Laboratories, including Divisional Vice President, Marketing and Business Development, for the International Division. Mr. Lloyd holds a Master of Science in Industrial Administration from Carnegie Mellon University and a Bachelor of Arts in Management Science from Westminster College, where he was a two-time basketball academic all-American.

Thomas Englese

Chief Commercial Officer

Tom Englese has served as our Chief Commercial Officer since July 2019. Prior to joining Aziyo, Mr. Englese served as General Manager of North America Hospital Therapies for Mallinckrodt Pharmaceuticals, a publicly traded pharmaceutical company, from April 2015 to July 2019, where Mr. Englese was responsible for the overall profit and loss management. Mr. Englese also served as Vice President Customer Operations from October 2008 to March 2015 for Ikaria, Inc., which was acquired by Mallinckrodt Pharmaceuticals in 2015, and was a member of the Business Development and Transaction team. From 2002 to 2008, Mr. Englese served as Senior Director of Business Operations at Baxter, a publicly traded healthcare company. Mr. Englese holds an M.B.A. from Pennsylvania State University and a B.S. in Marketing from Villanova University.

Read More…

Before joining Ikaria Mr. Englese held numerous roles with Baxter in the Anesthesia and Critical Care division. Mr. Englese holds a Master of Business Administration in Finance from The Pennsylvania State University and a Bachelor of Science in Marketing and Communications from Villanova University.

Matthew Ferguson

Chief Financial Officer

Matthew Ferguson has served as our Chief Financial Officer since September 2020. Prior to joining us, Mr. Ferguson served as Chief Financial Officer for Bossa Nova Robotics, a privately held robotics company serving major retailors, from September 2018 to July 2020. From January 2011 to August 2018, Mr. Ferguson held various management positions, including Chief Financial Officer, Chief Business Officer and Co-President, at Avinger, Inc., a publicly traded cardiovascular medical device company. From 2009 to 2010, Mr. Ferguson served as Chief Financial Officer at Tethys Bioscience, a provider of molecular diagnostic tests for cardiometabolic conditions. From 2008 to 2009, Mr. Ferguson served as the Chief Financial Officer at Proteolix, a biotechnology company developing treatments for cancer and autoimmune diseases. Mr. Ferguson also served as the Chief Financial Officer and Vice President of Finance and Business Development at FoxHollow Technologies, a publicly traded medical device company, from 2002 through its merger with ev3 in 2007. Mr. Ferguson holds an M.B.A. from the University of California at Berkeley, an M.S. in Mechanical Engineering from the University of Pennsylvania and a B.S. in Civil Engineering from Stanford University.

Read More…

From 2009 to 2010, Mr. Ferguson served as Chief Financial Officer at Tethys Bioscience, a provider of molecular diagnostic tests for cardiometabolic conditions. From 2008 to 2009, Mr. Ferguson served as the Chief Financial Officer at Proteolix, a biotechnology company developing treatments for cancer and autoimmune diseases. Mr. Ferguson also served as the Chief Financial Officer and Vice President of Finance and Business Development at FoxHollow Technologies, a publicly traded medical device company, from 2002 through its merger with ev3 in 2007. Mr. Ferguson holds a B.S. in Civil Engineering from Stanford University, an M.S. in Mechanical Engineering from the University of Pennsylvania and an M.B.A. from the University of California at Berkeley.

Darryl Roberts, Ph.D.

EVP, Operations & Product Development

Darryl Roberts, Ph.D. has served as our Executive Vice President and General Manager of the Musculoskeletal Product division from May 2016 to June 2020 and as our Executive Vice President, Operations and Product Development since July 2020. Prior to joining Aziyo, from 2013 to 2015 Dr. Roberts was Senior Vice President of Operations at TELA Bio, Inc., a biotechnology company, when the company gained regulatory clearance for a novel sterilization technique for tissue matrix. From 2007 to 2013, Dr. Roberts was a senior management team member for LifeCell Corp., a publicly traded company that developed and marketed tissue repair products, which was purchased by Kinetic Concepts, Inc. Dr. Roberts’ prior experience also includes various roles at Johnson & Johnson, where he was involved in the development and launch of several pharmaceutical and medical device products. Dr. Roberts holds a Ph.D. and a B.S. in Chemistry from the University of Alabama.

Read More…

His prior experience also includes involvement in the development and launch of a variety of pharmaceutical, medical device and consumer products at Johnson & Johnson, including Splenda®, ACUVUE® Brand Contact Lenses and the Cypher® Sirolumus-eluting Stent. He holds Bachelor of Science and Ph.D. degrees in Chemistry from the University of Alabama.

Jerome Riebman, M.D., M.A., FACS, FACC

Chief Medical Officer

Jerry Riebman, M.D. has served as our Chief Medical Officer since January 2020. Prior to joining Aziyo, Dr. Riebman served as lead to the U.S. Medical Heart Failure Program and the New Product Development team for Amgen Pharmaceuticals, Inc., a biotechnology company, from 2018 to 2020 and Director of External Relations and Advocacy for Amgen Pharmaceuticals in 2018. Dr. Riebman also served as Lead Medical Director of Cardiovascular for Novartis Pharmaceuticals Corporation, a pharmaceutical and healthcare company, from 2014 to 2018, where Dr. Riebman developed and marketed Heart Failure products in the Cardiovascular Therapeutic Area and developed and managed various studies for a heart failure clinical trials program. In 2003, Dr. Riebman co-founded Bay Innovation Group, LLC, an emerging medical device incubator, where he currently serves as Director of Scientific and Medical Affairs. He is also Board certified in Surgery and Thoracic Surgery. Dr. Riebman holds an M.D. from Temple University School of Medicine and a B.A. and an M.A. in Biology from Temple University. 

Read More…

Prior to this, he served as Executive Director of Medical Affairs for Ethicon Biosurgery, a Johnson & Johnson Global Surgery Group. Dr. Riebman is the inventor on over 14 medical device patents and has entrepreneurial and operational expertise in the development and commercialization of novel medical product solutions. He was also the founder and executive leader of several successful medical device and product companies. Prior to industry, Dr. Riebman’s clinical experience includes Cardiovascular and Thoracic Surgery practice in academic and community environments, including heart transplantation and heart assist devices. He completed medical studies at Temple University in Philadelphia, and trained in Internal Medicine at NYMC-Metropolitan Hospital Center, NY. He completed General Surgery training at Temple University, followed by a NHLBI research fellowship in the Artificial Heart Lab at the University of Utah, and a Cardiothoracic & Vascular Surgery residency at McGill University in Montreal. Dr. Riebman was board certified in both General Surgery and Thoracic Surgery, and is a Fellow of the American College of Surgeons and the American College of Cardiology.

Jeff Hamet

V.P. of Finance

Jeff Hamet is Vice President of Finance. Mr. Hamet joined Aziyo Biologics with over 25 years of senior-level finance, accounting and management experience primarily in the life sciences, medical services and high-technology industries. From 2013 through 2015, Mr. Hamet served as President and Chief Financial Officer of NeurExpand Brain Center LLC. From 2004 through 2012, Mr. Hamet was Vice President and Corporate Controller of Martek Biosciences Corporation.

Read More…

During Mr. Hamet’s tenure with Martek, the company experienced dramatic growth in revenues, profits and employees, culminating in its acquisition by Royal DSM N.V. for $1.1 billion. Prior to joining Martek, Mr. Hamet served as a financial executive at IGEN International, Inc. and ARBROS Communications, Inc. Mr. Hamet spent the first nine years of his career at Arthur Andersen LLP, an international public accounting firm. He holds a B.S. in accounting from the University of Maryland and is a Certified Public Accountant.

Courtney Guyer

V.P. of Marketing

Courtney Guyer joined Aziyo in 2018 as Vice President of Marketing bringing global leadership experience in established and start-up medical device companies across multiple therapies. Prior to joining Aziyo, Ms. Guyer served as Senior Director of Marketing at Medinol, an international cardiovascular startup where she led the pivotal launches of both Bare Metal and Drug Eluting Coronary Stent products. Previous to that she led US and Global Marketing teams at LifeCell for seven years working on both upstream and downstream launches and product portfolio projects.

Read More…

In addition, she has held various sales and marketing roles at Johnson & Johnson and Merck. Ms. Guyer holds a Masters of Business Administration degree from The Wharton School at the University of Pennsylvania and a Bachelor of Science in Biology from The Pennsylvania State University.

The Board of Directors.

Kevin Rakin

Chairman

Kevin Rakin has served as our chairman and a member of our board of directors since November 2015. Mr. Rakin is Co-founder of HighCape Partners, an investment fund and affiliate of Aziyo, and has been a general partner in HighCape Partners since 2013. Additionally, Mr. Rakin serves as Chief Executive Officer of HighCape Capital Acquisition Corp., a publicly traded affiliate of HighCape Partners, since June 2020. Since 2014, Mr. Rakin has also been a member of the board of directors of Oramed Pharmaceuticals Inc., a publicly traded pharmaceutical company, where Mr. Rakin serves on the Audit and Compensation Committee. Mr. Rakin has also served, and continues to serve, on the board of directors of several private companies, including Convexity Scientific Inc. since 2017, Nyxoah S.A., a publicly traded medical device company, since 2016 and Cybrexa, Inc. since 2016. Prior to and during the last five years, Mr. Rakin has served on the board of directors of various private and publicly traded biomedical and pharmaceutical companies, including Histogenics Corp., where Mr. Rakin served on the Audit and Compensation Committee, TELA Bio, Inc., Cheetah Medical, Inc. and Collagen Matrix, Inc. Mr. Rakin holds an M.B.A. from Columbia University and B.Com and B.Com (Hons) degrees from the University of Cape Town, South Africa.

Read More…

Previously, he was a Co-Founder, President and Chief Executive Officer of Genaissance Pharmaceuticals, Inc., a publicly traded pharmacogenomics company, until its merger with Clinical Data, Inc. in 2005. His Board memberships include Cheetah Medical, Inc. (Chairman), Cybrexa, Inc., and TELA Bio, Inc., as well as Histogenics Corp. and Collagen Matrix, Inc.

He has previously served as a Board member for Ipsogen SA, OMRIX Biopharmaceuticals, Inc., and Clinical Data, Inc. Mr. Rakin received an M.B.A. from Columbia University and B.Com and B.Com (Hons) degrees from the University of Cape Town.

W. Matthew Zuga

Board Member

Matt Zuga has served as a member of our board of directors since November 2015. Since October 2013, Mr. Zuga has been a Co-founder and partner of HighCape Partners, an investment fund and affiliate of Aziyo. Additionally, Mr. Zuga serves as Chief Financial Officer and Chief Operating Officer of HighCape Capital Acquisition Corp., a publicly traded affiliate of HighCape Partners, since June 2020. From August 2012 to September 2013, Mr. Zuga was a managing director of SyngentaVentures Pte Ltd, an investment vehicle of Syngenta Corp. He was also the founder and managing member of Red Abbey, an investment company, from January 2004 to August 2012. Prior to Red Abbey, Mr. Zuga was a managing director and the head of life sciences investment banking at Legg Mason from 1999 to 2003. He is currently on the board of directors of AgriMetis, LLC, Alba Therapeutics Corporation, MF Fire, Inc. and Virtue Labs LLC. Mr. Zuga holds an M.B.A. from the Kenan-Flagler Business School at the University of North Carolina at Chapel Hill and a B.S. in Business Administration/Finance from Ohio State University. 

Read More…

Prior to Red Abbey, Mr. Zuga was a managing director and the head of life sciences investment banking at Legg Mason from 1999 to 2003. He is currently on the boards of Aziyo Biologics, Inc., AgriMetis, LLC, Alba Therapeutics Corporation, MF Fire, Inc. and Virtue Labs LLC. Mr. Zuga received an MBA from the Kenan-Flagler Business School at the University of North Carolina at Chapel Hill and a B.S. in Business Administration/Finance from Ohio State University.

Maybelle Jordan

Board Member

Maybelle Jordan has served as a member of our board of directors since September 2020. Ms. Jordan has served as Vice President of Business Development of Biomerix Corporation, a biomaterials company focused on scaffold technology in the medical technology industry, since 2011, and as Chief Operating Officer for Biomerix from 2003 to 2011. Ms. Jordan also co-founded and served as President and CEO of MTrap Inc., a clinical-stage biomaterials company developing a cancer therapeutic device for treatment of advanced ovarian cancer, from 2015 to 2019. Ms. Jordan holds an M.B.A. from Harvard University and a B.S. in Biology from Yale University.

C. Randall Mills, Ph.D.

Board Member

Randy Mills, Ph.D. has served as a member of our board of directors since November 2015. Dr. Mills serves as Chief Executive Officer and is a member of the board of trustees of Sanford Burnham Prebys Medical Discovery Institute, a non-profit medical research institute. Dr. Mills served as Chief Executive Officer of the National Marrow Donor Program, a nonprofit international organization that provides bone marrow for transplantation, from July 2017 to February 2020. From May 2014 to July 2017, Dr. Mills served as Chief Executive Officer of the California Institute for Regenerative Medicine, which was created to fund stem cell research in California. Dr. Mills also served as Chief Executive Officer of Osiris Therapeutics, Inc., a publicly traded regenerative medicine company, from June 2004 to December 2013. Prior to and during the last five years, Dr. Mills has served on the board of directors of various nonprofit organizations, including Be The Match Foundation from July 2017 to February 2020 and TBI (now KeraLink), from August 2007 to December 2019 and of the Alliance for Regenerative Medicine, an international community of organizations focused on regenerative medicine, from January 2014 to January 2016. Dr. Mills holds a Ph.D. in Pharmaceutical Science and a B.S. in Microbiology from the University of Florida. 

Read More…

Prior to that, as President of the California Institute for Regenerative Medicine, he improved the speed and transparency of the agency. Randy has led significant growth in both private and publicly traded companies. As CEO of Osiris Therapeutics, he commercialized five cell therapy products and led the company through an IPO. Starting out, the subject of his graduate research, BioCleanse, became the core technology that launched Regeneration Technologies.

Brigid A. Makes

Board Member

Brigid Makes has served as a member of our board of directors since September 2020. Ms. Makes has served as an independent consultant for medical device and healthcare companies since July 2017, specifically advising on finance, accounting and funding responsibilities. From September 2011 to July 2017, Ms. Makes served as Senior Vice President and Chief Financial Officer of Miramar Labs, Inc., a biotechnology company focused on aesthetics and dermatology. From 2006 to 2011, Ms. Makes served as Senior Vice President and Chief Financial Officer of AGA Medical Corp, a medical device company developing interventional devices for the minimally invasive treatment of structural heart defects and peripheral vascular disorders. Prior to joining AGA, Ms. Makes held various positions at Nektar Therapeutics Inc. from 1999 to 2006, including serving as Chief Financial Officer. Since December 2019, Ms. Makes has also been a member of the board of directors of Mind Medicine (MindMed) Inc., a publicly traded neuro-pharmaceutical company, where Ms. Makes serves on the Audit Committee, the Compensation Committee and the Nominating/Governance Committee. Ms. Makes holds an M.B.A. from Bentley University and a Bachelor of Commerce degree in Finance & International Business from McGill University. 

Read More…

From 2006 to 2011, Ms. Makes served as Senior Vice President and Chief Financial Officer of AGA Medical Corp, a medical device company developing interventional devices for the minimally invasive treatment of structural heart defects and peripheral vascular disorders. Prior to joining AGA, Ms. Makes held various positions at Nektar Therapeutics Inc. from 1999 to 2006, including serving as Chief Financial Officer. Since December 2019, Ms. Makes has also been a member of the board of directors of Mind Medicine (MindMed) Inc., a publicly traded neuro-pharmaceutical company, where Ms. Makes serves on the Audit Committee, the Compensation Committee and the Nominating/Governance Committee. Ms. Makes holds an M.B.A. from Bentley University and a Bachelor of Commerce degree in Finance & International Business from McGill University.

Ronald Lloyd

President & CEO

Ron Lloyd has served as our President and Chief Executive Officer and as a member of our board of directors since June 2018. Prior to joining Aziyo, Mr. Lloyd served as Executive Vice President and President of Hospital Therapies of Mallinckrodt Pharmaceuticals, a publicly traded global pharmaceuticals company, from January 2016 to May 2018, where Mr. Lloyd reorganized the hospital business structure and completed four business development transactions. Mr. Lloyd also served as President of Immunology at Baxter, a publicly traded healthcare company, from April 2003 to December 2015, where Mr. Lloyd developed and implemented strategies to build the plasma business, the U.S. bioscience business and the regenerative medicine business. Mr. Lloyd holds a Master of Science in Industrial Administration from Carnegie Mellon University and a B.A. in Management Science from Westminster College.

Read More…

His tenure at Baxter included a leadership role in developing and implementing strategies to build a regenerative medicine business. Before joining Baxter, Ron served in a number of capacities at Abbott Laboratories, including Divisional Vice President, Marketing and Business Development, for the International Division. Mr. Lloyd holds a Master of Science in Industrial Administration from Carnegie Mellon University and a Bachelor of Arts in Management Science from Westminster College, where he was a two-time basketball academic all-American.

Want to Receive Updates About Upcoming Webinars?

Click below to join our webinar mailing list.

External links are provided for informational purposes only.
 
Aziyo bears no responsibility for the accuracy, legality or content of the external site or for that of subsequent links.
CANCEL     CONTINUE